Skip to main content

Drug Interactions between Hemgenix and Uniretic

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

hydroCHLOROthiazide moexipril

Applies to: Uniretic (hydrochlorothiazide / moexipril) and Uniretic (hydrochlorothiazide / moexipril)

Although hydroCHLOROthiazide and moexipril are frequently combined together, their effects may be additive on lowering your blood pressure. You may need a dose adjustment or special tests to safely take both medications. Contact your doctor if you have a reduced heart rate, dizziness, fainting, or headaches. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

moexipril etranacogene dezaparvovec

Applies to: Uniretic (hydrochlorothiazide / moexipril) and Hemgenix (etranacogene dezaparvovec)

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with other hepatotoxic agents may increase the risk of liver injury and decrease the therapeutic efficacy of fidanacogene elaparvovec and etranacogene dezaparvovec, liver-directed adeno-associated virus (AAV) vectors designed to help replace missing coagulation factor IX. Increased transaminase levels, particularly those observed in the first 3 to 4 months after administration of these agents, have been attributed to immune-mediated injury of transduced hepatocytes, which may decrease its therapeutic efficacy. In a prospective, open-label, single-arm, multinational clinical study of adult male patients with moderately severe to severe hemophilia B (n=45) receiving a single dose of fidanacogene elaparvovec (5 x 10[11] vector genomes [vg]/kg), 29 patients experienced increased transaminase levels greater than or equal to 1.5 times baseline. Of these patients, 28 received treatment with corticosteroids due to increased transaminases and/or a decline in factor IX activity, with a mean initiation time to corticosteroid therapy reported at 45 days. However, no serious adverse reactions were reported. Likewise, clinical studies with etranacogene dezaparvovec have also reported asymptomatic and mostly mild elevations in transaminases. The majority of elevated ALT levels returned to baseline; however, there were cases where they remained between 48 IU/L to 193 IU/L at two years post-administration of etranacogene dezaparvovec.

MANAGEMENT: As part of monitoring post-administration of fidanacogene elaparvovec, the manufacturer generally recommends monitoring of ALT and factor IX activity levels (e.g., one to two times a week for at least 4 months). The manufacturer of etranacogene dezaparvovec advises weekly transaminase level monitoring at weekly intervals for 3 months after its administration and, in patients with elevated levels, until those enzymes return to baseline. Initiation of corticosteroid therapy and monitoring of Factor IX activity should be considered in cases where ALT levels rise above the upper limit of normal or double baseline levels. The risk of additive hepatotoxicity and decreased therapeutic efficacy of fidanacogene elaparvovec should be considered after coadministration with other hepatotoxic agents. Alternative treatment may be required if an interaction is suspected. The manufacturer of etranacogene dezaparvovec does not provide specific recommendations concerning coadministration with other hepatotoxic agents. Local protocols and/or the product labeling of the concomitant drug(s) should be consulted for additional guidance.

Drug and food interactions

Moderate

moexipril food

Applies to: Uniretic (hydrochlorothiazide / moexipril)

It is recommended that if you are taking moexipril you should be advised to avoid moderately high or high potassium dietary intake. This can cause high levels of potassium in your blood. Do not use salt substitutes or potassium supplements while taking moexipril, unless your doctor has told you to.

Switch to professional interaction data

Moderate

hydroCHLOROthiazide food

Applies to: Uniretic (hydrochlorothiazide / moexipril)

HydroCHLOROthiazide and ethanol (alcohol) may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.